bpc-157 human clinical trial 2025 FDA's Review Of Peptides Signals A Growing Public Health Challenge bpc 157 human clinical trial

Learn why the body ages, when disease originates, and how top clinicians are changing their patients lives by treating the body

A recent phase 2 trial investigated the triple biased GLP-1/GIP/GCC receptors agonist retatrutide (LY3437943) in 338 patients with a mean age of 48 years and BMI of 37.3 kg/m 2 without diabetes (prediabetes in 36% participants) showing BW and WC reduction ranging from 8.7% to 24.2% and 6.5 cm to 19.6 cm in the 1 mg and 12 mg dose groups, respectively, at 48 weeks 41

In a recent phase 3 trial with patients with T2D and inadequate glycaemic control, the mean percentage change from baseline body weight with the 12-mg dose of retatrutide at 40 weeks was -15.3% [19]

Health Canada does not authorize it for personal, medical, or veterinary use

Analysis of samples was performed using an HPLC system